12:00 AM
Apr 22, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ampyra dalfampridine: Phase II data

Top-line data from a double-blind, crossover, U.S. Phase II trial in 83 patients who had experienced an ischemic stroke >=6 months prior to enrollment and who had chronic motor deficits showed that twice-daily 10 mg oral dalfampridine extended release (ER) tablets for 14 days significantly improved walking speed from baseline as measured by the T25FW test vs. placebo (p<0.05). Acorda also said that dalfampridine-ER showed...

Read the full 302 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >